Regenacy Pharmaceuticals to Present a Corporate Update at the 10th Annual Biotech Showcase

-- Update on Regenacy's innovative approach to treat diabetic and chemotherapy-induced peripheral neuropathies --
-- Growing evidence for the critical role of protein acetylation in neurological disorders and targeting deacetylases (HDAC6) validated in recent publication --

BOSTON – December 19, 2017 – Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for peripheral neuropathies, hemoglobinopathies and other severe chronic diseases by harnessing protein acetylation, announced today that Simon S. Jones, Ph.D., President and Chief Executive Officer of Regenacy, is scheduled to present a corporate update at the 10th Annual Biotech Showcase. Details for this presentation are as follows:

- Conference: 10th Annual Biotech Showcase (January 8-10, 2018)
- Location: Tuesday, January 9, 2018 at 10:00 a.m. Pacific time
- Time/Date: Hilton San Francisco Union Square in San Francisco, California

"We are excited for the opportunity to present on continued progress in the development of our lead clinical candidate ricolinostat in diabetic and chemotherapy induced peripheral neuropathies," said Simon Jones. "With ricolinostat poised to enter Phase 2 clinical trials in diabetic peripheral neuropathy, and the identification of selective HDAC1,2 inhibitors ready for development in hemoglobinopathies, we anticipate 2018 to be a year of significant progress for Regenacy."

The company also announced the recent publication of a paper co-authored by Dr. Matt Jarpe, Vice President of Research and Development for Regenacy, titled, "Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth," in the online edition of the peer-reviewed journal *Neurobiology of Disease*. "This publication presents the most recent research validating the neurorestorative potential of selective HDAC6 inhibition. Our unique approach to restoring lost nerve function in peripheral neuropathies by HDAC6 inhibition addresses pain as well as numbness, major unmet needs in chemotherapy-induced and diabetic peripheral neuropathy patients," said Matt Jarpe.

About Diabetic and Chemotherapy-Induced Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) are among the most common and widely reported examples of distal symmetric polyneuropathies. The symptoms of DPN and CIPN include pain, numbness, tingling, and temperature sensitivity in the hands and feet, and in the case of CIPN can limit chemotherapeutic dosage, delay additional treatment cycles, and lead to early termination of treatment – each potentially reducing the benefit of chemotherapy. Current treatments address only the pain and are minimally effective, temporary, addictive, and/or poorly tolerated and do not restore normal function.

About HDAC6 Inhibition
HDAC6, an intracellular deacetylase that regulates multiple intracellular processes such as protein degradation, intracellular transport, and mitochondrial function, has been implicated in the regulation of mitochondrial and protein transport along microtubules. Peripheral nerves, due to their length, are uniquely sensitive to metabolic and chemical insults that disrupt intracellular transport, leading to debilitating pain and numbness in part through mitochondrial dysfunction. Recent studies in animal models of DPN, CIPN and Charcot-Marie-Tooth disease, a hereditary neuropathy, have implicated HDAC6 as a promising therapeutic target to restore nerve function in the periphery and significantly alleviate the symptoms of pain, sensitivity and numbness.

About Regenacy
Regenacy Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of peripheral neuropathies, ciliopathic/polycystic diseases, hemoglobinopathies, cognitive disorders and oncology indications. The company's selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy's programs selectively inhibit histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in diabetic and other peripheral neuropathies and in ciliopathic/polycystic diseases, and selectively inhibit HDACs 1 and 2 to restore oxygen transport in orphan blood disorders such as sickle cell disease and beta-thalassemia, regenerate normal cognitive function in patients with psychiatric disorders, and restore normal bone marrow function through differentiation of acute myeloid leukemia (AML) cells. www.regenacy.com

CONTACTS:
Company Contact:
John Rocha, Chief Financial Officer
jrocha@regenacy.com

Media Contact:
MacDougall Biomedical Communications
Kari Watson or Kara Mazey, (781) 235-3060
kwatson@macbiocom.com
kmazey@macbiocom.com